Ph.D., economics, University of Michigan; B.A., economics and political science, Wellesley College
Summary of Experience
Dr. Chawla has more than 25 years of experience as an economist in the health care sector. Since joining Analysis Group in 2007, she has helped global biopharmaceutical, diagnostic, and medical device manufacturers - as well as development-stage companies - address product development and commercialization objectives, particularly as they relate to market access. Her work has spanned a wide range of therapeutic areas, including multiple indications in oncology. Her recent client work includes landscape assessments, economic modeling, and strategic plans to inform evidence generation in the context of product development and market access launch strategy; forecasts to help prioritize research and support licensing and venture funding discussions; payer research and advisory boards; and launch materials that communicate a product's clinical and economic value to support evidence-based reviews. Dr. Chawla recently led an engagement comprising a fully integrated market access strategy and related tactics to support the launch of a novel drug to treat an orphan disease.
Dr. Chawla's recent publications include an assessment of the impact of regulatory requirements for cardiovascular risk evaluation for diabetes therapies. She has served as a reviewer or referee for several journals, including Value in Health, Health Affairs, Health Services Research, Journal of the American Medical Association, and Journal of Business and Economic Statistics. Prior to joining Analysis Group, she was head of the health economics and outcomes research department at Genentech, Inc., where she also supported the oncology franchise.
Read Anita's profile